Inflammatory Arthritis Differential: RA vs PsA vs SpA Clinical Features
Sam Anderson
Clinical Pattern Recognition
Differentiating rheumatoid arthritis from psoriatic arthritis and spondyloarthritis is a clinical skill that determines the initial treatment approach and long-term management strategy. While all three conditions cause inflammatory arthritis, the joint distribution patterns, extra-articular features, laboratory profiles, and imaging findings differ in ways that are clinically distinguishing when evaluated systematically. For the rheumatologist, primary care physician, or internist evaluating a patient with new inflammatory joint symptoms, accurate pattern recognition at presentation prevents diagnostic delay and inappropriate initial therapy.
Rheumatoid arthritis (RA) classically presents with symmetric polyarthritis affecting the MCP, PIP, and wrist joints, with morning stiffness exceeding 60 minutes. Psoriatic arthritis (PsA) demonstrates five clinical patterns: asymmetric oligoarthritis (most common, 60-70%), symmetric polyarthritis (mimicking RA, 15-20%)[5], distal interphalangeal predominant (5%), axial disease (5%), and arthritis mutilans (less than 5%). Key PsA features (see also psoriasis biologics) that distinguish it from RA include DIP joint involvement, dactylitis (present in 40-50% of PsA)[5], enthesitis (Achilles, plantar fascia, lateral epicondyle), and nail dystrophy (pitting, onycholysis, oil drop sign), which are present in 80-90% of PsA patients with concomitant nail disease. Axial spondyloarthritis (axSpA) is characterized by inflammatory back pain (insidious onset before age 45, improvement with exercise, no relief with rest, nocturnal pain) present in over 75% of cases.
Serologic and Laboratory Differentiation
Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA/anti-CCP) are positive in 70-80% of RA patients, with anti-CCP having 95% specificity[2]. In PsA, RF is negative in 85-90% and anti-CCP in 90-95%, though 5-10% positivity can cause diagnostic confusion. Elevated CRP and ESR are present in 40-60% of RA and SpA flares but may be normal in 50% of PsA patients with active disease. HLA-B27 positivity occurs in 6-8% of the general population, 50-70% of PsA patients with axial involvement, and 80-90% of ankylosing spondylitis[4]. Ferritin, complement levels, and ANA help exclude other mimics such as SLE and adult-onset Still disease.
Imaging Distinctions
Radiographic features differ characteristically: RA shows periarticular osteopenia, uniform joint space narrowing, and marginal erosions at bare areas. PsA demonstrates a pathognomonic pattern of concurrent erosion and new bone formation (pencil-in-cup deformity), periostitis, asymmetric erosions, and DIP joint predilection. SpA imaging shows sacroiliitis (bilateral and symmetric in AS, often asymmetric in PsA) and syndesmophytes (marginal and flowing in AS versus paramarginal/nonmarginal in PsA). MRI with STIR sequences detects bone marrow edema at sacroiliac joints with sensitivity of 90% for active sacroiliitis[3], critical for diagnosing non-radiographic axSpA (nr-axSpA) before structural changes appear on conventional radiographs.
Classification Criteria Comparison
The 2010 ACR/EULAR RA classification criteria use a scoring system (score of 6 or above out of 10) incorporating joint distribution, serology (RF and anti-CCP), acute-phase reactants, and symptom duration. The CASPAR criteria for PsA require inflammatory articular disease plus 3 or more points from: current psoriasis (2 points), personal history of psoriasis, family history of psoriasis, dactylitis, juxta-articular new bone formation, RF negativity, and nail dystrophy (1 point each). Sensitivity is 91.4% and specificity 98.7%[1]. The ASAS criteria for axSpA require sacroiliitis on imaging (radiographic or MRI) plus one SpA feature, or HLA-B27 positivity plus two SpA features, with sensitivity of 82.9% and specificity of 84.4%[3].
Treatment Implications of Accurate Diagnosis
Accurate differentiation drives treatment selection. RA responds to methotrexate (15-25 mg weekly, first-line DMARD), while methotrexate has limited efficacy in axial SpA and enthesitis-predominant PsA. TNF inhibitors are effective across all three diseases. IL-17A inhibitors (secukinumab 150-300 mg, ixekizumab 80 mg monthly) are first-line biologic options for SpA and PsA but are ineffective in RA[6]. IL-23 inhibitors (guselkumab, risankizumab) show efficacy in PsA but not SpA axial disease. JAK inhibitors (tofacitinib, upadacitinib) are approved across all three conditions with varying efficacy profiles. Misdiagnosis of PsA as RA leads to suboptimal treatment of entheseal and axial components, while misdiagnosis of SpA delays appropriate biologic initiation. Concurrent gout should also be excluded in patients with inflammatory arthritis.
The Value of Getting the Diagnosis Right Early
The clinical importance of accurate pattern recognition in inflammatory arthritis cannot be overstated, because the treatment algorithms for RA, PsA, and SpA diverge in meaningful ways. A patient with RA who is misdiagnosed as having PsA may not receive methotrexate early enough, missing the window for optimal joint preservation. A patient with axial spondyloarthritis misdiagnosed as mechanical back pain may endure years of unnecessary imaging and ineffective treatments before receiving a biologic that could have controlled their disease from the outset. The key distinguishing features — symmetric small joint polyarthritis with positive RF/anti-CCP for RA, asymmetric oligoarthritis with dactylitis and enthesitis for PsA, inflammatory back pain with sacroiliitis for SpA — should be systematically assessed in every patient presenting with new inflammatory joint symptoms.
Limitations and Diagnostic Gray Zones
The clinical categories of RA, PsA, and SpA are useful frameworks but do not capture the full complexity of inflammatory arthritis. Overlap presentations are common — a patient with psoriasis and symmetric small joint polyarthritis may have PsA that resembles RA, or may have both conditions independently. Seronegative RA can be difficult to distinguish from early PsA without skin findings. And the classification criteria used in research (ACR/EULAR for RA, CASPAR for PsA, ASAS for SpA) are designed for clinical trials, not diagnosis — they have high specificity but imperfect sensitivity, meaning that some patients with genuine disease will not meet formal criteria. Clinical judgment, informed by the pattern recognition described here, remains essential for navigating these gray zones.
References
- Classification criteria for psoriatic arthritis: development of new criteria from a large international study PubMed 16871531
- A comparison of the diagnostic performance of anti-CCP and RF in rheumatoid arthritis: a meta-analysis PubMed 14872476
- The Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial spondyloarthritis PubMed 19208163
- Genetics and genomics of spondyloarthritis PubMed 19139213
- Psoriatic arthritis PubMed 25772764
- Secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis PubMed 28146459
Frequently Asked Questions
How do you distinguish PsA from RA serologically?
What are the CASPAR criteria for psoriatic arthritis?
Which biologics work in SpA and PsA but not RA?
What imaging distinguishes PsA from RA on radiographs?
Does methotrexate work for axial spondyloarthritis?
What HLA-B27 positivity rates differentiate SpA subtypes?
Explore This Topic in Ailva
Ailva is a free clinical intelligence platform for NPI-verified US physicians. Get evidence-based answers with verified citations from 16M+ indexed papers — plus free CME credits.
Founder of Ailva.ai | Former Director of Research and Author of 200+ Medically Reviewed Articles | Editor-in-Chief of EudaLife Magazine